SCHEDULE 13D/A: RA Capital Management Updates Significant Stake in Acumen Pharmaceuticals to 24.8% Amidst Share Dilution

RA Capital Management, L.P. and its affiliates have filed an amendment to their Schedule 13D, reporting a 24.8% beneficial ownership in Acumen Pharmaceuticals, Inc., a change primarily driven by an increase in the issuer's outstanding shares rather than new transactions by the reporting group.

Summary

• RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the "Reporting Persons") have filed Amendment No. 3 to their Schedule 13D concerning Acumen Pharmaceuticals, Inc.
• The Reporting Persons collectively beneficially own 15,016,063 shares of Acumen Pharmaceuticals, Inc. common stock.
• This ownership represents 24.8% of the Issuer's common stock outstanding, calculated based on 60,573,425 shares outstanding as of March 24, 2025, as reported in Acumen's Annual Report on Form 10-K.
• RA Capital Healthcare Fund, L.P. directly holds 13,043,179 shares, accounting for 21.5% of the class.
• Additional holdings include 1,300,034 shares by RA Capital Nexus Fund II, L.P., 588,850 shares by a separately managed account, and 84,000 shares underlying vested stock options held for RA Capital's benefit.
• No transactions involving Acumen Pharmaceuticals, Inc. securities have been executed by any Reporting Person within the past sixty days.
• The reported change in percentage ownership is attributed to an increase in the total number of outstanding shares of Acumen Pharmaceuticals, Inc.

Sentiment

Score: 5

Explanation: The filing is a routine update of beneficial ownership, indicating no transactions by the reporting persons in the last 60 days. While the percentage ownership decreased due to the issuer's share dilution, the investor group maintains a substantial numerical stake, suggesting continued long-term interest.

Positives

• A prominent institutional investor, RA Capital Management, maintains a substantial beneficial ownership stake of 24.8% in Acumen Pharmaceuticals, Inc., signaling continued long-term interest in the company.

Negatives

• The percentage ownership of the Reporting Persons has decreased due to an increase in the total number of outstanding shares of Acumen Pharmaceuticals, Inc., which implies dilution for existing shareholders.

Risks

• The increase in the number of outstanding shares of Acumen Pharmaceuticals, Inc. implies dilution, which can reduce the proportional ownership and value of existing shareholders' investments.

Future Outlook

NA

Management Comments

• "The Reporting Persons' ownership of the Issuer's securities includes (i) 13,043,179 shares of common stock held directly by the Fund; (ii) 1,300,034 shares of common stock held by RA Capital Nexus Fund II, L.P.; (iii) 588,850 shares of common stock held by a separately managed account; and a total of 84,000 shares underlying vested stock options held by Dr. Laura Stoppel for the benefit of RA Capital."
• "The percentage ownership reported in this amendment reflect an increase in the number of outstanding shares of the Issuer."
• "No transactions with respect to the securities of the Issuer have been effected during the past sixty days by any Reporting Person."

Industry Context

This filing is a standard disclosure of beneficial ownership by a significant institutional investor in a biotechnology company. While it does not provide specific industry trends, the continued substantial stake by RA Capital, a prominent healthcare-focused investor, suggests ongoing interest in the pharmaceutical sector, particularly in companies like Acumen Pharmaceuticals, Inc., which operates in the drug development space.

Stakeholder Impact

• Shareholders: Existing shareholders of Acumen Pharmaceuticals, Inc. experience dilution as the total number of outstanding shares has increased, reducing the proportional ownership of existing stakes.

Key Dates

Keywords

Acumen Pharmaceuticals, RA Capital Management, Schedule 13D/A, Beneficial Ownership, Institutional Investor, Shareholding, SEC Filing, Equity Stake, Dilution, Biotechnology, Pharmaceuticals